Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer

Despite theoretical risk of systemic corticosteroid impeding antitumor response, this retrospective cohort study (n=2459) found no link between use for an initial cutaneous immune-related adverse event and progression-free or overall survival, corroborating prior findings.

JAMA Dermatology